BAYER Supplement: Making Time for Change

Chairman’s introduction:
Macular degeneration and retinal disease, a major and growing worldwide health challenge

Prof Andrew Lotery, honorary consultant ophthalmologist, University Hospital Southampton and professor of ophthalmology, University of Southampton, chaired Bayer’s Satellite Symposium ‘Making time for change: using aflibercept solution for injection in a clinical setting’, Retina Day, the Royal College of Ophthalmologists Annual Congress, held 19
May 2014, Birmingham, UK.

“Age-related macular degeneration is the commonest cause of blindness in the western world,” explained Prof Lotery.1 “It affects up to 25 million people worldwide and up to 30,000 people are diagnosed with neovascular AMD each year in the United Kingdom alone.1,2 Studies evaluating age-specific prevalence of AMD show a strong rise with age,
and overall prevalence rates in the age groups 65-74 years and 75-84 years of 20 and 35 per cent, respectively.3 So there’s an escalating epidemic as the population ages and AMD is a major public health problem.”  Download Supplement - click here